Articles by Erin Slifka

Eli Lilly’s retatrutide will be in clinical trials for the next three years, but knockoff versions already abound.

The move comes a month after FDA advisers said the common ingredient phenylephrine is ineffective.

Talks are scheduled to resume Tuesday after some high-profile SAG-Aftra members offer additional dues and press for progress.

The Instagram and Facebook owner has been wrestling with how to best enforce its content rules in the midst of a brutal and chaotic war.

The 2024 race for the White House is reigniting the debate over EVs.

Americans wanted to get ambulances to Israel during a war. They had to do something they’ve always done in a way they’ve never done it.

A new generation of tiny one- and two-passenger electric cars is becoming available around the world. Americans aren’t interested.

In the emerging business of ‘social shopping,’ TikTok dominates the social and is spending big to improve the selling. Amazon dominates selling, and is working on the social.

In an interview, OpenAI’s CEO Sam Altman discusses job disruption, data and the ‘person-ness’ of bots.

The CEO’s second visit to China in roughly seven months highlights Apple’s increasingly complex relationship with the world’s second-largest economy.